Body recomposition after 35 — what changes and what works

They were. Not by you, and not in a way that discipline can simply override.

The body composition shift that begins in the mid to late thirties is driven by a convergence of biological changes that interact and compound each other in ways that make the usual interventions less effective, not because those interventions are wrong but because they were designed for a metabolic environment that no longer quite exists. Understanding what changed is the starting point for figuring out what actually works now.

The testosterone picture is the one most people know about, at least in outline. In men, testosterone levels begin a gradual decline from the late twenties or early thirties — not dramatically, but meaningfully over a decade. Testosterone drives muscle protein synthesis, governs the anabolic response to resistance training, and shapes where fat is stored and how readily it's mobilized. As it declines, the anabolic response to training blunts: the same resistance training session that used to produce a clear and sustained signal to build muscle produces a smaller and shorter-lived one. The muscle doesn't disappear overnight — the process is slow — but the composition drifts. Less lean mass is maintained through normal training, and fat accumulates more readily.

In women, the story is different in mechanism but similar in trajectory. Estrogen and progesterone fluctuations through perimenopause — which can begin in the late thirties or early forties, years before the final menstrual period — change fat distribution in a way that's biologically distinct from the male testosterone decline. Estrogen promotes fat storage in the hips and thighs; as estrogen levels become erratic and begin a net decline, that distribution shifts toward the abdomen and visceral deposits. Visceral fat — the fat stored around and within the abdominal organs — is metabolically active in ways that subcutaneous fat is not. It releases inflammatory cytokines, contributes to insulin resistance, and is harder to shift with diet and training than the subcutaneous fat that precedes it. The perimenopausal shift toward visceral fat deposition is one of the more consequential changes in midlife female physiology, and it doesn't respond to the same interventions that managed body composition in the estrogen-replete years.

Everyone — regardless of sex — experiences GH axis decline with age. Somatopause, the age-related decline in GH pulsatility, reduces the lipolytic signaling that GH provides: less fat breakdown, particularly in visceral depots. Growth hormone also supports lean mass maintenance through its role in protein synthesis and its interactions with IGF-1. As GH output declines, both sides of the body composition equation move in the wrong direction — more visceral fat, less muscle maintenance capacity — and they do so in a background of declining sex hormones that amplifies each effect.

Insulin sensitivity is the metabolic factor that ties these threads together. Aging, declining sex hormones, increasing visceral fat, reduced muscle mass, and declining physical activity all contribute to worsening insulin sensitivity over the years from 35 to 55. Insulin resistance means glucose is cleared from the blood less efficiently, fat storage is promoted, and the metabolic flexibility that allowed you to burn fat easily under a range of conditions becomes restricted. Muscles that are insulin resistant don't absorb glucose or amino acids as efficiently — both impair recovery and make the lean mass battle harder. The drift toward worse insulin sensitivity is not inevitable, but it requires more active management than it did at 28, and the same diet and exercise pattern that maintained good insulin sensitivity at 28 often produces measurably worse metabolic function at 45 simply because the background biology has changed.

Sarcopenia — the loss of skeletal muscle with age — begins earlier than most people realize. Muscle fiber cross-section begins declining in the late thirties in people who are not actively working against it, and the loss accelerates with each decade. The loss is not uniform: Type II fast-twitch fibers are lost preferentially over slow-twitch, which means the power and strength component of muscle function declines faster than endurance capacity. Visible muscle loss may not be apparent until significant function has already been lost, because the composition shift — more fat, less muscle, same weight — masks the change on a scale while showing up on a tape measure and in performance.

The conventional response to midlife body composition drift is correct at its core and increasingly insufficient in isolation. Resistance training is the most powerful intervention for preserving and building lean mass at any age, and the evidence that progressive resistance training can reverse sarcopenia and improve body composition in people in their forties and fifties is robust. The protein floor matters too — most midlife adults who think they're eating adequate protein are eating less than optimal for lean mass maintenance, and the research on protein needs in older adults consistently points higher than generic guidelines suggest, often toward 1.6 to 2.2 grams per kilogram of body weight or more. Sleep drives the anabolic environment in which training adapts the body — poor or shallow sleep blunts the GH pulse that drives lean mass maintenance and fat mobilization. These are not background factors. They are the primary levers.

The problem is that in midlife, these primary levers produce smaller effects than they used to. You can do everything right and still be fighting against a hormonal and metabolic environment that is working against composition goals. This is where the clinical conversation gets more complex, and where several emerging areas of research enter the picture.

Hormone replacement — testosterone therapy in men with confirmed low testosterone, estrogen and progesterone HRT in perimenopausal and menopausal women — carries the strongest evidence for addressing the hormonal component of midlife body composition change. This is not a peripheral supplement. Testosterone therapy in hypogonadal men produces real improvements in lean mass and reductions in fat mass, with effect sizes that outperform most other interventions. Estrogen therapy in menopausal women attenuates the visceral fat redistribution that characterizes post-menopausal body composition change. These are FDA-approved interventions with decades of evidence, and for people who qualify, they deserve to be in the conversation before most of what follows.

GLP-1 receptor agonists — originally developed for diabetes, now widely used for weight management — have become one of the most discussed interventions for midlife body composition. Compounds like semaglutide act on GLP-1 receptors to support insulin secretion, reduce appetite, slow gastric emptying, and improve insulin sensitivity. They produce meaningful reductions in body weight and visceral fat in the research and clinical literature. The FDA-approved versions (semaglutide, liraglutide, tirzepatide) are prescribed for weight management in people meeting specific criteria; microdose protocols using compounded versions are being explored in clinical contexts for people who don't meet the threshold for the full-dose indication but want the metabolic support. This is an evolving area where your prescribing provider's guidance on appropriate dose and indication matters.

GH axis support — Sermorelin, Ipamorelin, CJC-1295 — is researched for body composition effects including lean mass support and modest visceral fat reduction. The mechanism is the restoration of physiological GH signaling that has declined with age, with downstream effects on protein synthesis and lipolysis. Tesamorelin is an FDA-approved GHRH analog with a more specific indication: it's approved for the reduction of excess visceral fat in HIV-associated lipodystrophy, and it has been researched in the context of visceral fat reduction more broadly. The evidence for tesamorelin's visceral fat effects is stronger than for other GH-axis compounds, and it has a regulatory track record that compounded peptides lack. Its use outside the approved indication is off-label.

MOTS-c is a peptide encoded within mitochondrial DNA that has shown effects on metabolic flexibility, glucose metabolism, and exercise capacity in animal models. In preclinical work, MOTS-c improves insulin sensitivity and attenuates age-related metabolic decline. This is preclinical research — the human data is in early stages — but the mechanism of a mitochondria-derived peptide that acts on metabolic signaling is genuinely novel and the research is being watched closely in metabolic medicine.

BPC-157 connects to body composition indirectly, through its potential role in managing the training-related injuries and connective tissue issues that limit training volume in midlife athletes. If a chronic tendinopathy or recurring muscle strain is consistently interrupting the resistance training that drives lean mass maintenance, addressing that underlying limitation has body composition consequences. BPC-157's potential role in tendon and connective tissue support is discussed more thoroughly in other articles; the relevance here is that training continuity is itself a body composition intervention.

The honest framing — the one that applies before any compound enters the conversation — is that peptides and pharmaceuticals in this space are adjunctive to a foundation that has to be solid. Resistance training carries the most body composition evidence in midlife. Protein at appropriate levels is foundational. Sleep quality determines the anabolic environment in which everything else works. Stress management matters because chronic cortisol drives visceral fat deposition through direct mechanisms. If those foundations are not in place, no compound will compensate. If they are in place and the composition is still not responding, the question of whether the hormonal and metabolic environment needs clinical support is a legitimate one — and the most useful person to have that conversation with is a clinician who specializes in midlife metabolic health, who can evaluate your lab picture, your hormonal status, your insulin sensitivity, and your training and nutrition context, and who approaches body composition as the complex, multi-factor problem it actually is.

The drift isn't inevitable in its severity, but it does require different tools than the ones that worked at 28. Finding those tools starts with understanding why the old ones are producing diminishing returns — and that understanding, translated into a personalized clinical plan, is what the conversation with the right provider is for.